ABC | Volume 112, Nº3, March 2019

Original Article Bittencourt et al Myocardial fibrosis in hypertrophic cardiomyopathy Arq Bras Cardiol. 2019; 112(3):281-289 This is an open-access article distributed under the terms of the Creative Commons Attribution License 20. O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-74. 21. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm. 2005;2(8):814-9. 22. Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richmond DR, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(9):1192-4. 23. Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19(10):1118-26. 24. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta- analysis. Circ Heart Fail. 2012;5(5):552-9. 25. Adabag AS, Maron BJ, AppelbaumE, HarriganCJ, Buros JL, GibsonCM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51(14):1369-74. 26. Shiozaki AA, Senra T, Arteaga E, Martinelli Filho M, Pita CG, Ávila LF, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ ventriculartachycardiaevents inpatientswithhypertrophiccardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7(3):173-81. 27. Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosisoncardiacmagneticresonanceandcardiacoutcomes inhypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101(17):1406-11. 28. Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelinesriskpredictionmodelfortheprimarypreventionofsuddencardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829-35. 29. MaronBJ,CaseySA,ChanRH,GarberichRF,RowinEJ,MaronMS.Independent assessment of the European Society of Cardiology sudden death riskmodel for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757-64. 30. ChristiaansI,vanEngelenK,vanLangenIM,BirnieE,BonselGJ,ElliottPM,etal. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010;12(3):313-21. 31. OliveiraDC,AssunçãoFB,SantosAA,NacifMS.Cardiacmagneticresonance and computed tomography in hypertrophic cardiomyopathy: an update. Arq Bras Cardiol. 2016;107(2):163-72. 289